NY Approves First Human Trial of THC Pill VER-01 for Sciatica Pain

October 11, 2026

Photo by Mikhail Nilov via Pexels.

On October 1-2, 2026, New York's Cannabis Control Board quietly signed off on something that has nothing to do with dispensary licenses or retail store counts. Buried in the agenda was approval of application OCMRSCHAPP260002, authorizing a clinical trial that puts New York at the center of a genuinely novel piece of cannabis science: the first U.S. human trial of an oral THC solution called VER-01, aimed squarely at sciatica-related chronic pain.

VER-01 isn't some unregulated tincture pulled off a dispensary shelf. It already carries FDA Breakthrough Therapy Designation as a non-opioid candidate for chronic low back pain, a status reserved for drugs that show real promise against serious conditions and need an accelerated path through development. The New York trial, led by Dr. James Wild of Upstate Clinical Research Associates in Williamsville, and sponsored by the German pharmaceutical company Vertanical GmbH, is the next concrete step in testing whether that promise holds up in a rigorous clinical setting. For New York, it's a chance to establish itself as a serious research venue, not just a retail market. For the much larger population of chronic pain patients looking for alternatives to opioids, it's a data point worth watching closely.

What the Cannabis Control Board Approved

Photo by Vanderbilt_Law_School via Pixabay.

The approval itself is narrow and specific, which is exactly the point. The Cannabis Control Board granted the research license under application OCMRSCHAPP260002 during its October 1-2, 2026 meeting, and it authorizes use of VER-01 for one defined condition: chronically painful lumbosacral radiculopathy, the clinical name for what most people call sciatica. That's the nerve pain radiating from the lower back through the hip and down the leg, often tied to a herniated disc or spinal stenosis, and it's notoriously resistant to long-term treatment with standard analgesics. Dr. James Wild of Upstate Clinical Research Associates in Williamsville, New York, is the named principal investigator overseeing the study at that site. The trial is sponsored by Vertanical GmbH, a German pharmaceutical company that has been developing VER-01 as a prescription cannabis-derived medicine rather than a wellness product. New York isn't the only location running this protocol -- Upstate Clinical Research Associates is one of several U.S. research sites conducting the study in parallel, which is standard practice for multi-site trials needing enough enrolled patients to produce statistically meaningful results. This also isn't the Office of Cannabis Management's first foray into sponsoring or hosting clinical research. Back in May 2026, OCM separately greenlit an observational study looking at CBD and THC use among patients with inflammatory bowel disease. Taken together, the two studies suggest OCM is deliberately building out a research portfolio that sits alongside its commercial regulatory work, not as an afterthought to it.

Inside the Trial Design

Photo by PublicDomainPictures via Pixabay.

The sciatica study is built as a randomized, placebo-controlled trial, which is the design researchers trust most for separating a drug's real effect from expectation or coincidence. Participants will be split between those receiving VER-01 and those receiving a placebo, with neither patients nor likely the treating researchers knowing who's getting which during the active phase. The core question is straightforward: does VER-01 reduce pain more than placebo does, and by how much? That sounds basic, but it's the exact kind of controlled comparison that's been missing from most of the anecdotal evidence floating around cannabis and chronic pain for years. Beyond the headline pain-relief measurement, the protocol is also built to track durability. Lots of pain interventions show a short burst of relief that fades within weeks, so researchers will be following participants over an extended period to see whether any benefit from VER-01 actually holds up rather than tapering off. Safety monitoring runs on a parallel track throughout, not as a secondary afterthought -- long-term tolerability, side effect patterns, and any signs of misuse potential are core objectives here, not just efficacy. That emphasis makes sense given the drug's ultimate goal of being considered as a non-opioid alternative; a treatment that works but carries its own dependence risk wouldn't actually solve the problem it's aimed at. Worth underscoring: this New York site represents the first time VER-01 has been administered to human participants anywhere in the United States, making Dr. Wild's research team an early read on how the drug performs outside the European trials that got it this far.

What Exactly Is VER-01

VER-01 is a precisely engineered pharmaceutical product, not a cannabis extract in the loose sense most dispensary customers would recognize. Each dose comes as a 119 microliter oral solution, of which 50 microliters is full-spectrum cannabis extract, delivered with a dosing syringe rather than smoked, vaped, or swallowed as a capsule. That delivery method matters for a clinical trial -- it allows precise, repeatable dosing down to fractions of a milligram, something combustible or inhaled cannabis products can't reliably offer. The actual cannabinoid content per dose is tightly specified: 2.5 mg of THC, 0.1 mg of cannabigerol (CBG), and 0.02 mg of cannabidiol (CBD), suspended in sesame oil as the carrier excipient. That's a notably low THC amount compared to what's typical in recreational products, reflecting a formulation designed around therapeutic dosing rather than intoxication. The Breakthrough Therapy Designation the FDA granted on May 18, 2026 wasn't handed out casually -- it came on the strength of two Phase 3 randomized controlled trials that had already been completed, which showed significant pain relief relative to placebo, no signal of developing dependence among participants, and notably better gastrointestinal tolerability than what's typically seen with opioid painkillers. That combination -- meaningful relief without the GI distress and addiction risk that make opioids so difficult to prescribe long-term -- is precisely why regulators and researchers are paying attention. If VER-01 eventually clears the full approval process, Vertanical plans to bring it to market under the brand name Exilby.

Why Breakthrough Therapy Status Doesn't Mean Approval Yet

Photo by Artem Podrez via Pexels.

Breakthrough Therapy Designation sounds like it should fast-track a drug straight to pharmacy shelves, but that's a common misread of what the status actually does. It's an FDA mechanism meant to intensify the agency's engagement with a drug's development -- more frequent meetings, rolling review of data, closer guidance on trial design -- specifically because early evidence suggests the drug could offer a substantial improvement over existing treatments for a serious condition. It speeds up the conversation between sponsor and regulator. It does not substitute for the additional trial data the FDA still requires before granting market approval. Vertanical is treating it that way, too. Separate from the New York sciatica study, the company has already launched another pivotal Phase 3 trial in the U.S., and that trial's data -- not the sciatica results -- is what's expected to carry the most weight toward a future approval decision. Vertanical is targeting 2027 for that pivotal data to come in. Assuming the results support the drug's efficacy and safety case, the company is eyeing a New Drug Application submission to the FDA sometime in 2028. Even in a best-case scenario where every subsequent trial confirms what the Phase 3 studies already suggested, there are still multiple years of trial completion, data analysis, and FDA review standing between where VER-01 sits today and any pharmacist handing a bottle of Exilby across a counter.

OCM's Bigger Bet on Cannabis Science

Photo by Pexels via Pixabay.

OCM leadership framed the approval in terms that go well beyond one trial's outcome. Executive Director John Kagia called it an important moment both for cannabis research in New York and for the broader push toward evidence-based cannabis medicine, pointing out that decades of federal prohibition effectively blocked the kind of legitimate, well-funded research opportunities that other drug classes have had for generations. That's not rhetorical flourish -- federal scheduling has genuinely made it harder for researchers to study cannabis compounds with the same rigor applied to other compounds, which is part of why so much of what's circulated about cannabis and pain relief has remained anecdotal rather than clinically verified. Dr. Nakesha Abel, OCM's Director of Scientific Programs & Research, put a finer point on it: the goal is moving past anecdote and applying the same methodological rigor used to evaluate any other therapeutic. Abel noted that well-designed trials like this one don't just answer whether a treatment works in some general sense -- they clarify at what dose, for which patient populations, and with what risk profile, which is the actual information clinicians need before prescribing anything. New York appears to be positioning itself deliberately as a hub for this kind of pharmaceutical-grade cannabis science, running in parallel with its adult-use commercial marketplace rather than instead of it. None of this changes cannabis's federal legal status, and research access, physician participation rules, and even patient eligibility for trials like this vary considerably from state to state -- anyone interested in enrolling in or simply learning more about a trial like this should confirm the current rules in their own state before assuming anything applies to them.

A positive result out of Williamsville wouldn't just validate one research site's work -- it would add real weight to VER-01's broader case for FDA approval, inching the drug closer to becoming an actual pharmacy-shelf, non-opioid option for the millions of people managing chronic pain who'd rather not start down the opioid path in the first place. Sciatica alone affects a substantial share of adults at some point, and the current treatment menu -- NSAIDs, physical therapy, steroid injections, and eventually opioids for the toughest cases -- hasn't exactly been a satisfying set of options.

That said, nobody should mistake Breakthrough Therapy Designation or a newly approved trial for an approved drug. The gap is still measured in years: pivotal Phase 3 data isn't expected until 2027, an NDA filing is penciled in for 2028 at the earliest, and FDA review after that would add more time still. Plenty can go sideways between a promising Phase 3 result and a final approval letter.

The more interesting long-game question might be about New York itself. Will the state treat this trial as a one-off curiosity, or will it use the OCM's growing research portfolio -- this sciatica study, the IBD observational work from earlier in the year, whatever comes next -- as a deliberate pitch to attract more pharmaceutical-grade cannabis research? A state that can credibly offer both a mature commercial cannabis market and a serious clinical research infrastructure has something most other legal states can't yet claim.